Result of GM

Oncimmune Holdings PLC

10 March 2025

 

Oncimmune Holdings Plc

("Oncimmune" or the "Company")

Result of General Meeting

The General Meeting of Oncimmune Holdings Plc was held at 201 Temple Chambers, 3-7 Temple Avenue, London, EC4Y 0DT on 10 March 2025 at 11:00 a.m.

All resolutions put to members were passed on a poll. All resolutions were passed as ordinary resolutions.

The number of votes cast for and against each of the resolutions proposed, and the number of votes withheld were as follows:

Resolution	Votes for	%	Votes against	%	Votes withheld
Resolution 1 (Report and Accounts)	27,510,816	99.56%	122,242	0.44%	57,398
Resolution 2 (Remuneration Report)	25,826,233	94.66%	1,455,827	5.34%	408,396
Resolution 3 (Appointment of Auditor)	26,465,373	95.75%	1,175,200	4.25%	49,883
Resolution 4 (Remuneration of Auditor)	27,479,703	99.42%	160,870	0.58%	49,883

The full text of each resolution is available in the Notice of General Meeting, published on the Company's website.

For further information:

[e-mail]

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Geoff Nash, Callum Davidson, Trisyia Jamaludin (Corporate Finance)

Nigel Birks (Life Science Specialist Sales)

Ondraya Swanson (Corporate Broking)

[phone]

Zeus (Joint Broker)

Dominic King

[phone]

About Oncimmune

Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile. Taking a platform approach to generating insights, Oncimmune is partnering with global pharmaceutical and biotech companies, as well as contract research organisations (CROs) to discover novel biomarkers for the development of more targeted and effective therapies across many immune-mediated diseases. Our mission at Oncimmune is to enable precision medicine. We help our partners to discover novel biomarkers, drug targets and predict treatment efficacy through the application of our platform. We are able to do this by deploying our world class scientific team and our cutting-edge technology platform, built on years of experience in the field. Our aim is to make this an essential tool in drug discovery and development.

Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.

For more information, visit www.oncimmune.com

 

END